We develop therapies that can "reprogram" the immune system
At Orikine Bio, we develop therapies that can "reprogram" the immune system, much like how software engineers rewrite faulty code to fix computer systems.
Our Foldikine™ platform is designed to engineer bi-specific cytokines, molecules that send precise, targeted instructions to immune cells that have gone off track. By "reprogramming" these cells, we restore proper immune function, providing groundbreaking solutions for conditions like autoimmune diseases and chronic inflammation.
Our team brings together leading experts in immunology, protein engineering, and biotechnology. We are driven by a passion to translate cutting-edge research into therapies that can rewrite the future of medicine by correcting immune system errors at their core.


Orikine Bio was founded in 2022 as a spin-off from the Centre for Genomic Regulation (CRG) in Barcelona, a world-renowned hub of genomic and biomedical research.
Orikine’s heritage is deeply rooted in innovation, using the same computational precision that scientists use to decode complex genetic information. Through our Foldikines™ platform, we are now writing the next chapter in immune system reprogramming — developing therapies that correct immune dysfunction with the precision of a finely tuned software program.
With strong support from investors like Asabys and AdBio, Orikine Bio has secured €5.5 million in seed funding to accelerate life-changing therapies into preclinical development.